This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Raffaghello, L. Articles by Pistoia, V. Search for Related Content PubMed PubMed Citation Articles by Raffaghello, L. Articles by Pistoia, V.

Expression and Functional Analysis of Human Leukocyte Antigen Class I Antigen-Processing Machinery in Medulloblastoma

Laboratories of ¹ Oncology and ² Pathology, ³ Department of Pediatric Neurosurgery, G. Gaslini Institute, Genoa, Italy; ⁴ Department of Immunology, Roswell Park Cancer Center, Buffalo, New York; and ⁵ Laboratory of Hematology and Oncology, Department of Pediatrics, University of Padova, Padua, Italy

Requests for reprints: Lizzia Raffaghello, Laboratory of Oncology, G. Gaslini Institute, Genoa, Italy. Phone: 39-10-5636342; Fax: 39-10-3779820; E-mail: lizziaraffaghello{at}ospedale-gaslini.ge.it.

Defects in the expression and/or function of the human leukocyte antigen (HLA) class I antigen-processing machinery (APM) components are found in many tumor types. These abnormalities may have a negative impact on the interactions of tumor cells with host's immune system and on the outcome of T cell–based immunotherapy. To the best of our knowledge, no information is available about APM component expression and functional characteristics in human medulloblastoma cells (Mb). Therefore, in the present study, we have initially compared the expression of APM components in Mb, an embryonal pediatric brain tumor with a poor prognosis, with that in noninfiltrating astrocytic pediatric tumors, a group of differentiated brain malignancies with favorable prognosis. LMP2, LMP7, calnexin, ß2-microglobulin–free heavy chain (HC) and ß2-microglobulin were down-regulated or undetectable in Mb lesions, but not in astrocytic tumors or normal fetal cerebellum. Two Mb cell lines (DAOI and D283) displayed similar but not superimposable defects in APM component expression as compared with primary tumors. To assess the functional implications of HLA class I APM component down-regulation in Mb cell lines, we tested their recognition by HLA class I antigen-restricted, tumor antigen (TA)–specific CTL, generated by stimulations with dendritic cells that had been transfected with Mb mRNA. The Mb cell lines were lysed by TA-specific CTL in a HLA-restricted manner. Thus, defective expression of HLA class I–related APM components in Mb cells does not impair their ability to present TA to TA-specific CTL. In conclusion, these results can contribute to optimize T cell–based immunotherapeutic strategies for Mb treatment. [Cancer Res 2007;67(11):5471–8]